35989-06-1

Usage

Uses

Used in Coordination Chemistry:
[2,3'-Bipyridin]-5-amine is used as a ligand for metal complexes in coordination chemistry. Its unique structure allows it to form stable complexes with metals, which can be utilized in various applications, including catalysis and the development of new materials.
Used in Organic Synthesis:
In the field of organic synthesis, [2,3'-Bipyridin]-5-amine serves as a key building block for the creation of more complex molecules. Its reactivity and structural properties make it a valuable component in the synthesis of various organic compounds.
Used in Medicinal Chemistry:
[2,3'-Bipyridin]-5-amine is used as a potential pharmaceutical candidate in medicinal chemistry. Its unique structure and properties may contribute to the development of new drugs and therapeutic agents, particularly in the areas of pharmaceuticals and materials science.
Used in Catalysis:
[2,3'-Bipyridin]-5-amine's potential as a ligand for metal complexes also makes it an important compound for use in catalysis. Its ability to form stable complexes with metals can enhance the efficiency of catalytic reactions, leading to improved industrial processes and the development of new catalytic systems.
Overall, [2,3'-Bipyridin]-5-amine is a versatile compound with a wide range of potential applications across various industries, making it an important compound for further study and development.

Upstream product

• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 1692-25-7 3-pyridylboronic acid 
• 4487-59-6 2-bromo-5-nitropyridine 
• 14805-03-9 5-nitro-[2,3]bipyridinyl 

Downstream Products

• 264617-08-5 [2,3']bipyridinyl-5-yl-carbamic acid phenyl ester 

Relevant academic research and scientific papers

NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS

The present invention relates to novel benzamides derivatives of formula (I) as modulators of PPAR-gamma receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of PPAR-gamma receptor, such as cancer; metabolic diseases, inflammatory diseases, respiratory disorders, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases and renal diseases.

Design, synthesis, anticancer activity and docking studies of theophylline containing 1,2,3-triazoles with variant amide derivatives

A new series of theophylline analogues containing 1,2,3-triazoles with different amide groups (22-41) has been designed and synthesized, and their biological activities have been evaluated as potential anticancer agents. The anticancer activities of the synthesized compounds were studied in four cancer cell lines viz. lung (A549), colon (HT-29), breast (MCF-7) and melanoma (A375). Furthermore, these compounds were screened for computational ADME and Lipinski's analysis followed by molecular docking and binding energy calculations against the various therapeutic targets involved in cell proliferation. The in vitro results demonstrate that compounds 22, 27, 36 and 40 have pivotal anticancer activity. Among these, compounds 22 and 27 have significant cytotoxic activity in all three cell lines; the in silico docking studies also reveal that compounds 22, 27 and 36 have good dock scores, binding affinities and binding energies towards human epidermal growth factor receptor 2. This is the first report to demonstrate theophylline hybrids containing 1,2,3-triazoles as potential anticancer agents.

NAPHTHALENE DERIVATIVE

The present invention provides compounds which can regulate VCP activity. The present invention provides the compound of formula (I) (R is as defined in the description) or oxides, esters, prodrugs, pharmaceutically acceptable salts or solvates thereof. The compounds can regulate VCP activity, and thus are useful for treating VCP-mediated diseases such as neurodegenerative diseases.

Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: Identification of 5-methyl-1-[[2-[(2-methyl-3- pyridyl)oxy]5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent

The evolution, synthesis, and biological activity of a novel series of 5-HT(2C) receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT(2C) affinity and selectivity over 5- HT(2A) receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT(2B) receptor. Compounds from this series are inverse agonists at the human cloned 5-HT(2C) receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.